Cargando…

Sensitivity and responsiveness of the EQ-5D-3L in patients with uncontrolled focal seizures: an analysis of Phase III trials of adjunctive brivaracetam

PURPOSE: Preference-based measures are required to measure the impact of interventions for cost-effectiveness analysis. This study assessed the psychometric performance of the EQ-5D-3L in adults with uncontrolled focal (partial-onset) seizures. METHODS: Data from three Phase III studies of an antiep...

Descripción completa

Detalles Bibliográficos
Autores principales: Mukuria, Clara, Young, Tracey, Keetharuth, Anju, Borghs, Simon, Brazier, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5309305/
https://www.ncbi.nlm.nih.gov/pubmed/28004320
http://dx.doi.org/10.1007/s11136-016-1483-3
_version_ 1782507687942029312
author Mukuria, Clara
Young, Tracey
Keetharuth, Anju
Borghs, Simon
Brazier, John
author_facet Mukuria, Clara
Young, Tracey
Keetharuth, Anju
Borghs, Simon
Brazier, John
author_sort Mukuria, Clara
collection PubMed
description PURPOSE: Preference-based measures are required to measure the impact of interventions for cost-effectiveness analysis. This study assessed the psychometric performance of the EQ-5D-3L in adults with uncontrolled focal (partial-onset) seizures. METHODS: Data from three Phase III studies of an antiepileptic drug (adjunctive brivaracetam; n = 1095) were used. Analysis included correlations between EQ-5D-3L and Quality of Life in Epilepsy Inventory (QOLIE-31P) and seizure frequency. Known group validity was based on ability of the EQ-5D-3L to discriminate between baseline QOLIE-31P total scores, seizure type and number of antiepileptic drugs using effect sizes (ES). Responsiveness assessed proportions reporting highest or lowest scores, overall change using standardized response means (SRM) and change by responder and clinician/patient evaluation groups using ES. RESULTS: Correlations were weak to moderate (ρ = 0.2–0.4) between EQ-5D-3L dimensions and QOLIE-31P subscales, apart from medication effects (ρ < 0.1); seizure frequency was not associated with either measure. Known group analysis had small ES. A quarter (24.9%) of patients had a baseline EQ-5D-3L utility score of 1 (full health) but lower average QOLIE-31P scores. SRMs were small (<0.1) in EQ-5D-3L compared with 0.1–0.4 for QOLIE-31P subscales. Results across the studies were mixed for responder status and clinician/patient evaluation of improvement for EQ-5D-3L. CONCLUSIONS: EQ-5D-3L had weak-to-moderate correlations with QOLIE-31P and varied with QOLIE-31P severity groups, but showed less responsiveness than QOLIE-31P. Given this lack of sensitivity, EQ-5D-3L may not be appropriate for measuring the impact of interventions in cost-effectiveness analysis in this population and disease-specific preference-based measures may be more appropriate. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s11136-016-1483-3) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5309305
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-53093052017-02-28 Sensitivity and responsiveness of the EQ-5D-3L in patients with uncontrolled focal seizures: an analysis of Phase III trials of adjunctive brivaracetam Mukuria, Clara Young, Tracey Keetharuth, Anju Borghs, Simon Brazier, John Qual Life Res Article PURPOSE: Preference-based measures are required to measure the impact of interventions for cost-effectiveness analysis. This study assessed the psychometric performance of the EQ-5D-3L in adults with uncontrolled focal (partial-onset) seizures. METHODS: Data from three Phase III studies of an antiepileptic drug (adjunctive brivaracetam; n = 1095) were used. Analysis included correlations between EQ-5D-3L and Quality of Life in Epilepsy Inventory (QOLIE-31P) and seizure frequency. Known group validity was based on ability of the EQ-5D-3L to discriminate between baseline QOLIE-31P total scores, seizure type and number of antiepileptic drugs using effect sizes (ES). Responsiveness assessed proportions reporting highest or lowest scores, overall change using standardized response means (SRM) and change by responder and clinician/patient evaluation groups using ES. RESULTS: Correlations were weak to moderate (ρ = 0.2–0.4) between EQ-5D-3L dimensions and QOLIE-31P subscales, apart from medication effects (ρ < 0.1); seizure frequency was not associated with either measure. Known group analysis had small ES. A quarter (24.9%) of patients had a baseline EQ-5D-3L utility score of 1 (full health) but lower average QOLIE-31P scores. SRMs were small (<0.1) in EQ-5D-3L compared with 0.1–0.4 for QOLIE-31P subscales. Results across the studies were mixed for responder status and clinician/patient evaluation of improvement for EQ-5D-3L. CONCLUSIONS: EQ-5D-3L had weak-to-moderate correlations with QOLIE-31P and varied with QOLIE-31P severity groups, but showed less responsiveness than QOLIE-31P. Given this lack of sensitivity, EQ-5D-3L may not be appropriate for measuring the impact of interventions in cost-effectiveness analysis in this population and disease-specific preference-based measures may be more appropriate. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s11136-016-1483-3) contains supplementary material, which is available to authorized users. Springer International Publishing 2016-12-21 2017 /pmc/articles/PMC5309305/ /pubmed/28004320 http://dx.doi.org/10.1007/s11136-016-1483-3 Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Article
Mukuria, Clara
Young, Tracey
Keetharuth, Anju
Borghs, Simon
Brazier, John
Sensitivity and responsiveness of the EQ-5D-3L in patients with uncontrolled focal seizures: an analysis of Phase III trials of adjunctive brivaracetam
title Sensitivity and responsiveness of the EQ-5D-3L in patients with uncontrolled focal seizures: an analysis of Phase III trials of adjunctive brivaracetam
title_full Sensitivity and responsiveness of the EQ-5D-3L in patients with uncontrolled focal seizures: an analysis of Phase III trials of adjunctive brivaracetam
title_fullStr Sensitivity and responsiveness of the EQ-5D-3L in patients with uncontrolled focal seizures: an analysis of Phase III trials of adjunctive brivaracetam
title_full_unstemmed Sensitivity and responsiveness of the EQ-5D-3L in patients with uncontrolled focal seizures: an analysis of Phase III trials of adjunctive brivaracetam
title_short Sensitivity and responsiveness of the EQ-5D-3L in patients with uncontrolled focal seizures: an analysis of Phase III trials of adjunctive brivaracetam
title_sort sensitivity and responsiveness of the eq-5d-3l in patients with uncontrolled focal seizures: an analysis of phase iii trials of adjunctive brivaracetam
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5309305/
https://www.ncbi.nlm.nih.gov/pubmed/28004320
http://dx.doi.org/10.1007/s11136-016-1483-3
work_keys_str_mv AT mukuriaclara sensitivityandresponsivenessoftheeq5d3linpatientswithuncontrolledfocalseizuresananalysisofphaseiiitrialsofadjunctivebrivaracetam
AT youngtracey sensitivityandresponsivenessoftheeq5d3linpatientswithuncontrolledfocalseizuresananalysisofphaseiiitrialsofadjunctivebrivaracetam
AT keetharuthanju sensitivityandresponsivenessoftheeq5d3linpatientswithuncontrolledfocalseizuresananalysisofphaseiiitrialsofadjunctivebrivaracetam
AT borghssimon sensitivityandresponsivenessoftheeq5d3linpatientswithuncontrolledfocalseizuresananalysisofphaseiiitrialsofadjunctivebrivaracetam
AT brazierjohn sensitivityandresponsivenessoftheeq5d3linpatientswithuncontrolledfocalseizuresananalysisofphaseiiitrialsofadjunctivebrivaracetam